

DREAMS Consortium Meeting Marks Key Milestone in Advancing Rare Neuromuscular Disease Research

Partners align strategy and coordination as the project enters a crucial early phase of scientific and clinical development.

12 November 2025

The DREAMS project - *Drug Repurposing with Artificial Intelligence for Muscular Disorders* - has held its second consortium meeting, bringing together its European partners to review progress and reinforce collaboration as the project advances its integrated approach to rare neuromuscular disease research.

Funded under Horizon Europe, DREAMS aims to accelerate therapeutic discovery for five rare neuromuscular disorders — **Centronuclear Myopathy, Duchenne Muscular Dystrophy, Emery–Dreifuss Muscular Dystrophy type 2, Pompe disease and Danon disease** — through a methodology combining iPSC-derived muscle cell models, AI-supported target and molecule identification, and adaptive clinical trial design. During the meeting in Paris, partners aligned timelines, discussed coordination needs across work packages and reviewed the early steps required to ensure methodological consistency. The session focused particularly on the preparation of disease-relevant cellular assays, data workflows for AI integration and preliminary planning for future clinical design activities.

The DREAMS consortium consists of nine organisations across six countries: **CECS/I-Stem (coordinator), INSERM, AFM-Téléthon, University College London (UCL), Kantify, Assistance Publique–Hôpitaux de Paris, Universidade de Coimbra, Technion – Israel Institute of Technology and Zabala Innovation**. This multidisciplinary team reflects the project’s ambition to build a reusable discovery platform capable of identifying shared therapeutic opportunities across multiple neuromuscular diseases.

As the project moves forward, the consortium remains committed to strengthening cooperation between disciplines and ensuring that all activities progress in line with the scientific, societal and regulatory objectives of DREAMS.

More information: www.dreamshorizon.eu

Contact Information: Bea Quintillá (bquintilla@zabala.es)



UK Research
and Innovation

DREAMS project. Funded by the European Union under 101080229-2. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union (EU) or European Research Executive Agency (REA). Neither the EU nor REA can be held responsible for them.